Skip to main content

Table 3 Effect of NVP-AEW541 (IC70) on the cell cycle distribution of pancreatic cancer cell lines

From: Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

Cell line/treatment Sub-G1 G0/G1 S G2/M
BxPc3     
Control 7.7±1.4 55.6±2.3 25.4±5 10.8±1.8
NVP-AEW541 7.9±2.7 69.7±4.5* 15.7±2.9 6.2±1.1
AsPC-1     
Control 1±0.02 46.1±0.3 31.8±0.2 19.5±0.1
NVP-AEW541 3.9±0.2* 47.1±0.4 35.7±1.5 14±2.6
Capan-1     
Control 3.8±0.3 50.6±2.5 25.5±3.1 18.6±1.1
NVP-AEW541 7±0.2* 53.6±1.3 23±1.8 15.1±1.4
PT45     
Control 2.3±0.6 74.4±4.3 12.3±2.8 10.1±1
NVP-AEW541 10.2±2.7* 59.8±1.4* 19.7±4.8 9.9±2.4
Miapaca-2     
Control 4.6±2.6 76.1±2.2 10±1.3 8.6±0.5
NVP-AEW541 5.5±2.7 81±1.3 9.4±0.8 4.5±3.7
PANC1     
Control 5.6±1.5 48.3±4.6 11.6±0.1 32.7±4.7
NVP-AEW541 9.3±0.5 72.4±2.1* 12.1±0.3 4.9±0.4*
FA6     
Control 13.8±2 48.3±3.1 25.4±4.8 11.2±0.4
NVP-AEW541 36.8±2.8* 33.2±1.2* 22.2±1.3 6.9±2.2
  1. Each population is expressed as percentage of gated cells (mean of three independent experiments ± S.D).* depicts statistically significant difference (p<0.05) compared to control values.